2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Molecular Testing, Omics Technologies, Bioinformatics, Computational Biology, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Non-Biological Therapies, Pharmacology, Biological Processes, Apoptosis, Genomics, Immune Mechanism, Metabolism, Molecular Biology, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Quality Improvement, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Myeloid Malignancies, Chronic Myeloid Malignancies, CLL, Research, Fundamental Science, Translational Research, Clinical Research, Real-World Evidence, Study Population, Human, Adult
PAPER

3862 Chimeric antigen receptor T-cells against the IGHV1-69 B cell receptor specifically eliminate chronic lymphocytic leukemia tumoral B cells

Gabrielle Croston, Jean Lemoine, MD2, Ivan J Cohen, PhD3, Audrey C Bochi-Layec, BS4, Laura Astara, MD5, Reagan Burke6, Roman H Khadka, PhD7, Seul Jung, BS8, Alberto Carturan, MD9, Antonio Imparato, MD10, Peter Michener11, Anushka Anant Padmanabhan12, Patrizia Porazzi, PhD13, Anastasia Iatrou14, Andreas Agathangelidis15, Giorgio Inghirami, MD16, Joseph Fraietta, PhD17, Vijay Bhoj, MD, PhD18, Stephen J Schuster, MD19, Paolo Ghia, MD, PhD20, Kostas Stamatopoulos, MD, PhD21, Marco Ruella, MD22
1 Abramson Cancer Center, Philadelphia, Pennsylvania, United States, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States, University of Pennsylvania, Philadelphia, Pennsylvania, United States
2 Abramson Cancer Center, Philadelphia, Pennsylvania, United States, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States, University of Pennsylvania, Philadelphia, Pennsylvania, United States
3 Abramson Cancer Center, Philadelphia, Pennsylvania, United States, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States, University of Pennsylvania, Philadelphia, Pennsylvania, United States
4 Abramson Cancer Center, Philadelphia, Pennsylvania, United States, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States, University of Pennsylvania, Philadelphia, Pennsylvania, United States
5 Abramson Cancer Center, Philadelphia, Pennsylvania, United States, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States, University of Pennsylvania, Philadelphia, Pennsylvania, United States
6 Abramson Cancer Center, Philadelphia, Pennsylvania, United States, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States, University of Pennsylvania, Philadelphia, Pennsylvania, United States
7 Abramson Cancer Center, Philadelphia, Pennsylvania, United States, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States, University of Pennsylvania, Philadelphia, Pennsylvania, United States
8 Abramson Cancer Center, Philadelphia, Pennsylvania, United States, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States, University of Pennsylvania, Philadelphia, Pennsylvania, United States
9 Abramson Cancer Center, Philadelphia, Pennsylvania, United States, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States, University of Pennsylvania, Philadelphia, Pennsylvania, United States
10 Abramson Cancer Center, Philadelphia, Pennsylvania, United States, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States, University of Pennsylvania, Philadelphia, Pennsylvania, United States
11 Abramson Cancer Center, Philadelphia, Pennsylvania, United States, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States, University of Pennsylvania, Philadelphia, Pennsylvania, United States
12 Abramson Cancer Center, Philadelphia, Pennsylvania, United States, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States, University of Pennsylvania, Philadelphia, Pennsylvania, United States
13 Abramson Cancer Center, Philadelphia, Pennsylvania, United States, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States, University of Pennsylvania, Philadelphia, Pennsylvania, United States
14 Centre for Research and Technology Hellas, Thessaloniki, Greece
15 Centre for Research and Technology Hellas, Thessaloniki, Greece
16 Weill Cornell Medicine, New York-Presbyterian Hospital, New York City, United States
17 Abramson Cancer Center, Philadelphia, Pennsylvania, United States, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States, University of Pennsylvania, Philadelphia, Pennsylvania, United States
18 Abramson Cancer Center, Philadelphia, Pennsylvania, United States, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States, University of Pennsylvania, Philadelphia, Pennsylvania, United States
19 Abramson Cancer Center, Philadelphia, Pennsylvania, United States, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States, University of Pennsylvania, Philadelphia, Pennsylvania, United States
20 Università Vita-Salute San Raffaele, Milan, Italy
21 Centre for Research and Technology Hellas, Thessaloniki, Greece
22 Abramson Cancer Center, Philadelphia, Pennsylvania, United States, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States, University of Pennsylvania, Philadelphia, Pennsylvania, United States

Introduction:

B cell receptor (BcR) signaling, through both antigen-dependent and antigen-independent mechanisms, plays a central role in chronic lymphocytic leukemia (CLL) progression. Thus, BcR-directed targeting is a crucial opportunity in treatment strategy. Chimeric antigen receptor (CAR) T-cell therapy targeting CD19 (CART19) has revolutionized the treatment of B cell malignancies. However, major limitations persist, especially in treating CLL: only a fraction of patients achieve durable responses, and responders experience bystander B cell depletion, which can result in prolonged B cell aplasia and infection risk. We hypothesized that targeting the BcR with a CAR T-cell therapy would provide a clone-specific, pathology-relevant strategy for the treatment of patients with unmutated CLL (U-CLL) while sparing the normal B cell repertoire.

Methods and Results: 

We first analyzed the immunoglobulin heavy-chain variable gene (IGHV) in a total of 76,126 newly diagnosed CLL cases using next generation sequencing. We found IGHV1-69 to be the most frequent BcR IGHV in CLL, accounting for 12.6% of newly diagnosed cases. Furthermore, we found that the vast majority (90%) of IGHV1-69 CLL are U-CLL, known to be associated with a more aggressive disease and a poorer prognosis. IGHV1-69 CLL were even further enriched in a cohort of patients treated at our institution with CART19 (n=38), accounting for 32% of these heavily pre-treated patients. Conversely, IGHV1-69 is only rearranged in less than 5% of normal B cells. Altogether, these data identified IGHV1-69 U-CLL as a specific therapeutic challenge. 

Therefore, we developed an anti-IGHV1-69 CART (CART1-69) using a single-chain variable fragment derived from the monoclonal antibody hG6.3 in a heavy-to-light orientation with a CD8 hinge and a 4-1BB costimulatory domain. To assess in vitro function, we used Mec1 WT, a CLL cell line that endogenously expresses a non-IGHV1-69 BcR. We then developed a Mec1 derivative that exogenously expresses the IGHV1-69 BcR (Mec1 IGHV1-69) after CRISPR-Cas9 knockout of the native BcR. Using these cell lines, we evaluated CART1-69 for cytotoxicity, proliferation, and cytokine secretion. We used untransduced T-cells (UTD) as a negative control and CART19 as a positive control. When co-cultured with Mec1 WT not expressing IGHV1-69, CART1-69 demonstrated minimal cytotoxicity, limited proliferation, and no cytokine secretion. However, with Mec1 IGHV1-69, CART1-69 showed robust, antigen-specific activity: cytotoxicity towards tumor cells was 74% after 48 hours at a 1:4 effector-to-target ratio (p<0.0001 compared to UTD), and was significantly proliferated after 120 hours when co-cultured with irradiated tumor cells. CART1-69 also secreted IFN-γ and IL-2 in response to Mec1 IGHV1-69 (p<0.0001 compared to UTD), indicating specific activation against an IGHV1-69+ cell line. CART19 showed potent killing, proliferative activity, and cytokine secretion regardless of IGHV1-69 status, recognizing CD19 on both target cell lines. We next evaluated CART1-69 efficacy against primary CLL samples: CART1-69 killed IGHV1-69 U-CLL but not IGHV1-69- CLL (73% vs. 5%, respectively, p<0.0001), while CART19 killed both. To further evaluate CART1-69, we engrafted NSG mice with Mec1 IGHV1-69 cells (1e6 cells, injected subcutaneously), followed by CART1-69 treatment (1.25e6 CAR+ cells, injected intravenously). We found that CART1-69 significantly prolonged median survival compared to UTD (60 days vs. 27 days, p<0.05), confirming the results of in vitro experiments.

Conclusions: 

We found IGHV1-69 to be the most frequent BcR IGHV in a large cohort of newly diagnosed CLL, with the vast majority being unmutated. Given the IGHV1-69 U-CLL frequency and its associated poor prognosis, we thus developed a novel CAR T-cell therapy specific against IGHV1-69, CART1-69. CART1-69 demonstrated antigen-specific cytotoxicity, proliferation, and cytokine production in vitro, including towards primary CLL cells. Furthermore, it exhibited significant anti-tumor activity and prolonged survival in vivo. Thus, CART1-69 appears as a promising therapy to achieve specific targeting of IGHV1-69 U-CLL.

Gabrielle Croston: No relevant conflicts of interest to declare.